My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 107

    1.

    Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis.

    Gaede P, Pedersen O.

    Diabetes. 2004 Dec;53 Suppl 3:S39-47. Review.PMID: 15561920 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study.

    Pedersen O, Gaede P.

    Metabolism. 2003 Aug;52(8 Suppl 1):19-23. Review.PMID: 12939735 [PubMed - indexed for MEDLINE]Related articles

    3.

    Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.

    N Engl J Med. 2003 Jan 30;348(5):383-93.PMID: 12556541 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Oral antidiabetic agents: current role in type 2 diabetes mellitus.

    Krentz AJ, Bailey CJ.

    Drugs. 2005;65(3):385-411. Review.PMID: 15669880 [PubMed - indexed for MEDLINE]Related articles

    5.

    Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

    Gaede P, Vedel P, Parving HH, Pedersen O.

    Lancet. 1999 Feb 20;353(9153):617-22.PMID: 10030326 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Clinical trial of the month. The STENO-2 study: a plea for global and intensive management of the type 2 diabetic patient]

    Scheen AJ, Estrella F.

    Rev Med Liege. 2003 Feb;58(2):109-11. French. PMID: 12693313 [PubMed - indexed for MEDLINE]Related articles

    7.

    Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study.

    Vaag AA.

    Endocr Pract. 2006 Jan-Feb;12 Suppl 1:89-92. Review.PMID: 16627389 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of a multifactorial intervention on mortality in type 2 diabetes.

    Gaede P, Lund-Andersen H, Parving HH, Pedersen O.

    N Engl J Med. 2008 Feb 7;358(6):580-91.PMID: 18256393 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    [Recent advances in the management of diabetes mellitus]

    Paquot N, Philips JC, Radermecker R, Lefèbvre P.

    Rev Med Liege. 2007 May-Jun;62(5-6):317-23. Review. French. PMID: 17725201 [PubMed - indexed for MEDLINE]Related articles

    10.

    [Prevention of cardiovascular disease in type 2 diabetic patients]

    Yokota C.

    Nippon Rinsho. 2003 Jul;61(7):1161-6. Review. Japanese. PMID: 12877078 [PubMed - indexed for MEDLINE]Related articles

    11.

    [Pharmacological therapy of obesity]

    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

    G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian. PMID: 18773755 [PubMed - indexed for MEDLINE]Related articles

    12.

    Intensive therapy for diabetes through influence on innate immune system.

    Li ZZ, Liu JB, Li L, Jiao L, Chen L.

    Med Hypotheses. 2009 Jun;72(6):675-6. Epub 2009 Mar 4.PMID: 19264419 [PubMed - indexed for MEDLINE]Related articles

    13.

    Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for?

    Gaede P, Pedersen O.

    Horm Metab Res. 2005 Apr;37 Suppl 1:76-82. Review.PMID: 15918115 [PubMed - indexed for MEDLINE]Related articles

    14.

    Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

    Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A.

    Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005613. Review.PMID: 17443605 [PubMed - indexed for MEDLINE]Related articles

    15.

    [Current aspects and future perspectives of pharmacotherapy or type II diabetes]

    Ben Salem C, Elouni B, Bouraoui K.

    Tunis Med. 2004 Oct;82(10):905-13. Review. French. PMID: 15686186 [PubMed - indexed for MEDLINE]Related articles

    16.

    Antihypertensive treatment and multifactorial approach for renal protection in diabetes.

    Fioretto P, Solini A.

    J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S18-21. Review.PMID: 15938027 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Metformin monotherapy for type 2 diabetes mellitus.

    Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.

    Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. Review.PMID: 16034881 [PubMed - indexed for MEDLINE]Related articles

    18.

    The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.

    Hoerger TJ, Ahmann AJ.

    J Manag Care Pharm. 2008 Feb;14(1 Suppl C):S2-14; quiz 15-6. Review.PMID: 18240890 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

    Grima DT, Thompson MF, Sauriol L.

    Pharmacoeconomics. 2007;25(3):253-66.PMID: 17335310 [PubMed - indexed for MEDLINE]Related articles

    20.

    [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care]

    Pittrow D, Stalla GK, Zeiher AM, Silber S, März W, Pieper L, Klotsche J, Glaesmer H, Ruf G, Schneider HJ, Lehnert H, Böhler S, Koch U, Wittchen HU.

    Med Klin (Munich). 2006 Aug 15;101(8):635-44. German. PMID: 16896570 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity